- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00801151
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer
A Phase I Clinical Trial of Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Anticipated)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Nantes Saint Herblain, France, 44805
- Centre Rene Gauducheau
-
Paris, France, 75005
- Institut Curie
-
Toulouse, France, 31052
- Institut Claudius Regaud
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient must have a histologically-confirmed metastatic or locally advanced cancer.
- Patient is ≥ 18 years of age on day of signing informed consent.
- Patient must have performance status < 1 on the ECOG performance scale.
Patient must have adequate organ function as indicated by the following laboratory values:
- Hematological: absolute neutrophil count (ANC) ≥ 1,5x109/L; platelets ≥ 100 x109/L; hemoglobin ≥ 9 g/dL
- Renal : calculated creatinine clearance b ≥ 60 mL/min
- Hepatic : serum total bilirubin ≤ 1.5 X ULN ; AST (SGOT) and ALT (SGPT) ≤ 2.5 X ULN; alkaline phosphatase if > 2.5 X ULN, then liver fraction should be ≤ 2.5 X ULN
Coagulation : prothrombin time (PT) ≤1.2 X ULN ; partial thromboplastin time (PTT) ≤1.2 X ULN
- Patients should have adequate bone marrow function without the current use of colony stimulating factors
- Creatinine clearance should be calculated according to Cockcroft-Gault formula
- For female patients of childbearing potential: must have a negative serum pregnancy test within 72 h before drug administration
- Male and Female patients of childbearing potential must agree to use an adequate method of contraception throughout the study starting with Visit 1 and for at least 30 days after the last dose of study medication.
- Patient has voluntarily agreed to participate by giving written informed consent.
- Patient must be available for periodic blood sampling, study related assessments, and management at the treating institution of the duration of the study.
Exclusion Criteria:
- Patient is currently participating or has participated in a study with an investigational compound or device within 30 days of signing informed consent.
- Patient pre-treated with one of the two investigational compounds (ie; vinorelbine or vorinostat)
- Patients with active CNS metastases and/or carcinomatous meningitis and uncontrolled brain metastases are excluded. However, patients with CNS metastases who have completed a course of therapy would be eligible for the study provided they are clinically stable for 3 months prior to entry as defined as: (1) no evidence of new or enlarging CNS metastasis (2) off steroids or on a stable dose of steroids.
- Patient has known hypersensitivity to the components of study drug or its analogs.
- Patient has a history or current evidence of any condition, therapy, or lab abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in the best interest of the patient to participate
- Patient has known psychiatric or substance abuse disorders that would interfere with cooperation with the requirements of the trial.
- Patient is, at the time of signing informed consent, a regular user (including "recreational use") of any illicit drugs or had a recent history (within the last year) of drug or alcohol abuse.
- Patient is pregnant or nursing,
- Patient is known to be Human Immunodeficiency Virus (HIV)-positive.
- Patient has known history of Hepatitis B or C.
- Patient with a history of a prior malignancy with the exception of cervical intraepithelial neoplasia; basal cell carcinoma of the skin; adequately treated localized prostate carcinoma with PSA <1.0; or who has undergone potentially curative therapy with no evidence of that disease for five years, and who is deemed at low risk for recurrence by his/her treating physician
- Patient has preexisting grade 2 or higher neuropathy
- Patients who had received radiotherapy to more than 30% of the bone marrow surface (i.e whole pelvis)
- Patients under law protection
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Vorinostat, vinorelbine
Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration.
|
Vorinostat will be administered orally at the starting dose of 200 mg po qd 7/21(weekly schedule) in combination with the standard dose of vinorelbine 25mg/m² per week as intravenous infusion over 10 minutes starting 4 hours after vorinostat administration. Barring dose limiting toxicities the dose of vorinostat will escalate in several steps (300 mg po qd 7/21 days, 300 mg po qd 21/21 days, 400 mg po qd 7/21 days, 400 mg po qd 21/21 days). Patients may receive a maximum of 6 cycles of study medication.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To determine the maximum tolerated dose (MTD) of vorinostat administered in combination with standard doses of vinorelbine.
Time Frame: at the end of the trial
|
at the end of the trial
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
To assess the pharmacokinetics of vorinostat and vinorelbine when administered in combination.
Time Frame: at the end of the trial
|
at the end of the trial
|
To assess the safety and tolerability of this regimen in advanced solid tumors.
Time Frame: at the end of the study
|
at the end of the study
|
To make a preliminary assessment of the efficacy of the combination, in terms of response rate, response duration, time to response and time to progression.
Time Frame: At the end of the trial
|
At the end of the trial
|
To evaluate predictive pharmacodynamic biomarkers (e.g., histone acetylation in peripheral blood) when vorinostat is administered in combination with vinorelbine.
Time Frame: At the end of the trial
|
At the end of the trial
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jean-Pierre Delord, MD, PhD, Institut Claudius Regaud
Study record dates
Study Major Dates
Study Start
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ESTIMATE)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 07 GENE 05
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Solid Tumour
-
SynCore Biotechnology Co., Ltd.No longer availableMalignant Solid Tumour
-
ImmunityBio, Inc.CompletedMalignant Solid TumourUnited States
-
SCRI Development Innovations, LLCNovartisCompletedMalignant Solid TumourUnited States
-
Fuda Cancer Hospital, GuangzhouShenzhen Hank Bioengineering InstituteCompletedMalignant Solid TumourChina
-
IpsenCompleted
-
ASLAN PharmaceuticalsCompleted
-
Boehringer IngelheimCompletedMalignant Solid TumourGermany
-
The Netherlands Cancer InstitutePfizerUnknownMalignant Solid TumourNetherlands
-
The University of Texas Health Science Center at...Merck Sharp & Dohme LLCCompleted
-
University of PittsburghBristol-Myers SquibbCompletedMalignant Solid TumourUnited States
Clinical Trials on Zolinza (vorinostat), vinorelbine
-
Peter MacCallum Cancer Centre, AustraliaGlaxoSmithKline; Merck Sharp & Dohme LLCTerminatedFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone LymphomaAustralia
-
Johns Hopkins All Children's HospitalTerminatedCentral Nervous System TumorsUnited States
-
Fox Chase Cancer CenterNational Comprehensive Cancer NetworkCompletedLocally Advanced Non-small Cell Lung CancerUnited States
-
National Center for Tumor Diseases, HeidelbergMerck Sharp & Dohme LLC; University Hospital HeidelbergCompleted
-
University of CalgaryUnknown
-
Merck Sharp & Dohme LLCCompleted
-
Merck Sharp & Dohme LLCCompleted
-
Indiana University School of MedicineBayerCompletedMyelodysplastic Syndromes | Leukemia, Myeloid, Acute | Leukemia, Promyelocytic, AcuteUnited States
-
Medical University of GrazTerminatedLeiomyosarcoma | Endometrial Stromal Tumors | Carcinosarcomas UterineAustria
-
Groupe Francophone des MyelodysplasiesMerck Sharp & Dohme LLCCompletedMyelodysplastic SyndromesFrance